Beijing Kanglison Medical Technology Development

Beijing Kanglison Medical Technology Development is a comprehensive pharmaceutical research and development company based in China. Founded in 2001, the company operates as a high-tech enterprise providing Contract Research Organization (CRO) services, including CMC, clinical trial management, and regulatory registration. Beyond its service offerings, Kanglison is actively engaged in the development of both high-end generic drugs and innovative small molecule therapeutics, particularly in the metabolic and cardiovascular therapeutic areas. The company is led by Dr. Cheng Zengjiang and has established a significant presence in the Chinese pharmaceutical R&D landscape.